Investing.comDoubao · 实盘不做把握 7/10不做原因:已被定价
北京时间·🕒 发布 20:04:30·⟳ 抓取 20:05:50 +1m20s·⚡ 决策 10-26 20:09:43 +3m53s·18.9 小时前
Investing.com 重述 Iambic（IAM）IAM1363 在 ESMO（10月23日）公布的 I/1b 期更新数据，无新增事实
本条 Investing.com 稿件是对 Iambic 10月23日 ESMO 壁报数据的滞后（+3天）AI 重述，未引入任何新患者数、新剂量结论或公司新指引；数据已在10月23日美股交易日被定价，当日 IAM 收跌2.79%、近5日约-11%，盘前对该重述仅微涨0.5%且成交量极小，无新鲜 edge。
📄 原文Investing.com↗ 原文
Iambic presents updated data on HER2 cancer drug IAM1363
Five things to watch in markets in the week ahead SAN DIEGO - Iambic Therapeutics, Inc. (NASDAQ:IAM) presented updated…
不做 Iambic Therapeutics（IAM.US）
STALE/PRICE_IN：核心 I/1b 期更新数据已于2026-10-23 ESMO 首发并在当日及随后交易日消化（首发日-2.79%、5日约-11%）；本条 Investing.com 为3天后聚合站 AI 重述、无新增事实，盘前亦无重估反应，无入场 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
IAM1363 的 I/1b 期更新数据（ORR 36%、颅内 ORR 41%、安全性可控）已于10月23日 ESMO 公开并完成首个交易日定价；10月26日 Investing.com 为聚合站 AI 重述、无新增事实，属于已消化旧闻，不做。
消息传播链
- 聚合站 AI 生成稿重述10月23日 ESMO 数据，无新数字、无公司新表态，属滞后转载。市场反应:10-26 盘前 IAM 报约14.33美元、+0.49%，盘前量仅约136股，基本无反应。
关键理由
- 数据本身对研发型 biotech 属温和正面（重度经治、含 T-DXd/tucatinib 经治人群仍有36% ORR 与41%颅内应答、无4/5级 AE），但已于10月23日披露。
- 公司2026年10月中旬刚 IPO（市值约6.8亿美元），股价上市后持续回落，市场对该数据的真实解读偏谨慎而非惊喜。
主要风险
- 样本量小（疗效可评估53例、颅内22例）、单臂 I 期且无对照，疗效与 tucatinib 等的比较优势尚未证实；后续 II/III 期读出存在不确定性。
- 次新股流通盘小、波动大，若本轮 ESMO 后有券商上调评级或合作传闻，股价可能脱离基本面短线波动。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-23 · 影响 weakens
真实首发日 IAM 收跌2.79%、近5日-10.9%，未检索到因该数据带来的正面跳空或上调；市场反应本身否定了'未被定价的利好'假设。
检索:Iambic IAM1363 ESMO October 23 2026 stock reaction analyst downgrade 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认不入场：缺乏新鲜 edge，且首发日反应为负。
方向:未做外部先例统计：本条无可交易的新增催化（3天前会议数据的聚合重述），价格反应窗口已过，先例幅度不改变 STALE/PRICE_IN 结论。
涨幅量级:不适用；不以历史 biotech 会议读出来为一条滞后重述设定止盈止损。
形态:可观察的直接价格证据是 IAM 在真实首发日（10-23）收跌且随后5日走弱，提示该数据本身偏 sell-the-no-news/不及高预期。
工具执行结果 · 成功 6 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 244 ms
{"result": "search_processed_events:agent query=`iam1363 phase 1/1b intracranial response 960mg esmo madrid october 23 | iambic therapeutics iam1363 her2 updated data esmo 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.9/72 小时、2991 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - web_search 成功 doubao_search · 1,947 ms
豆包搜索结果（原始查询:Iambic Therapeutics IAM1363 ESMO 2026 updated data October 23 press release IAM1363 36% partial response；API SearchType:web） - web_search 成功 doubao_search · 1,378 ms
豆包搜索结果（原始查询:Iambic Therapeutics IAM stock IPO NASDAQ:IAM market cap IAM1363；API SearchType:web） - stock_quote 降级 stock_tools HTTP · 752 ms
{ - web_search 成功 doubao_search · 1,988 ms
豆包搜索结果（原始查询:"IAM1363" ESMO 2026 Iambic 122 patients 960mg updated data press release；API SearchType:web） - web_search 成功 doubao_search · 1,561 ms
豆包搜索结果（原始查询:Iambic IAM stock October 23 2026 ESMO data reaction shares；API SearchType:web） - web_search 成功 doubao_search · 1,902 ms
豆包搜索结果（原始查询:Iambic IAM1363 ESMO October 23 2026 stock fell reaction analyst Phase 1 data；API SearchType:web）
原文全文
展开原文 · 2,042 字
Five things to watch in markets in the week ahead
SAN DIEGO - Iambic Therapeutics, Inc. (NASDAQ:IAM) presented updated clinical data for IAM1363, a HER2 tyrosine kinase inhibitor, at the European Society for Medical Oncology Congress in Madrid on October 23, according to a press release statement.
The Phase 1/1b trial enrolled 122 participants with HER2-altered advanced cancers as of August 31. Participants had received a median of three prior treatment regimens, with 61% having received trastuzumab deruxtecan and 36% having received tucatinib. Breast cancer represented 38% of cases and non-small cell lung cancer 19%, while 44% of participants had central nervous system metastases.
Among 53 participants with targetable HER2 alterations receiving doses of 960 mg or higher once daily, 36% achieved partial response, 38% had stable disease, and 26% experienced progressive disease according to RECIST v1.1 criteria. For intracranial activity in 22 participants, 41% achieved partial response, 55% had stable disease, and 5% showed progressive disease per modified RANO-BM criteria.
More than half of participants dosed at 960 mg once daily remain on study treatment. Three participants with HER2-positive breast cancer who had previously received both trastuzumab deruxtecan and tucatinib achieved confirmed intracranial partial responses and remain on treatment.
In the 68 participants receiving 960 mg once daily, 5.9% experienced grade 3 treatment-related adverse events and 5.9% had treatment-related adverse events leading to dose modifications. No grade 4 or 5 treatment-related adverse events occurred in this group. The most common adverse events of any grade were diarrhea (59%), nausea (53%), and vomiting (49%).
The study comprises dose escalation, dose optimization, monotherapy expansion cohorts at 960 mg, and combination cohorts. Parts 3 and 4 remain open to enrollment at sites in the U.S., Europe and Asia.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN DIEGO - Iambic Therapeutics, Inc. (NASDAQ:IAM) presented updated clinical data for IAM1363, a HER2 tyrosine kinase inhibitor, at the European Society for Medical Oncology Congress in Madrid on October 23, according to a press release statement.
The Phase 1/1b trial enrolled 122 participants with HER2-altered advanced cancers as of August 31. Participants had received a median of three prior treatment regimens, with 61% having received trastuzumab deruxtecan and 36% having received tucatinib. Breast cancer represented 38% of cases and non-small cell lung cancer 19%, while 44% of participants had central nervous system metastases.
Among 53 participants with targetable HER2 alterations receiving doses of 960 mg or higher once daily, 36% achieved partial response, 38% had stable disease, and 26% experienced progressive disease according to RECIST v1.1 criteria. For intracranial activity in 22 participants, 41% achieved partial response, 55% had stable disease, and 5% showed progressive disease per modified RANO-BM criteria.
More than half of participants dosed at 960 mg once daily remain on study treatment. Three participants with HER2-positive breast cancer who had previously received both trastuzumab deruxtecan and tucatinib achieved confirmed intracranial partial responses and remain on treatment.
In the 68 participants receiving 960 mg once daily, 5.9% experienced grade 3 treatment-related adverse events and 5.9% had treatment-related adverse events leading to dose modifications. No grade 4 or 5 treatment-related adverse events occurred in this group. The most common adverse events of any grade were diarrhea (59%), nausea (53%), and vomiting (49%).
The study comprises dose escalation, dose optimization, monotherapy expansion cohorts at 960 mg, and combination cohorts. Parts 3 and 4 remain open to enrollment at sites in the U.S., Europe and Asia.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
17895805bd· 2026-10-26 20:09 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前